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Abstract
Background: Zoonotic visceral leishmaniasis (ZVL) caused by Leishmania (Leishmania) infantum is an important
disease in humans and dogs. Different mammal species are reservoirs but dogs are considered to be the main
one. Phlebotomine sand flies are the proven vector. Four systemic insecticides approved for their use in dogs were
previously selected based on their potential to be used in endemic countries as part of the control programs of
ZVL. These insecticides are proved to be safe and effective against the on-label insects and parasites, but there is
no information about their activity against phlebotomine sand flies.
Methods: The phlebotomine mortality of four systemic insecticides in dogs was evaluated using two randomized
clinical trials. For the first trial, thirty dogs were randomly allocated into five groups: four treatments and one control, of
equal size. The treatments evaluated were: Guardian®SR, Elanco (moxidectin); Comfortis®, Elanco (spinosad); Bravecto®,
Merck Animal Health (fluralaner); and NexGard®, Merial (afoxolaner). Blood from dogs was taken at days 2, 4, 21 and 31
post-treatment (trial 1). The compound that showed the highest efficacy was selected for a second trial (trial 2) with 20
dogs sampled at days 0, 2, 4, 7, 14, 18, 32, 39, 51 and 84 post-treatment. Membrane feeding bioassays with Phlebotomus
papatasi were used to evaluate the phlebotomine mortality efficacy of the different treatments. Phlebotomine mortality
was observed every 24 h following the membrane feeding during 5 days. A mixed model for a negative
binomial logistic regression, and a Cox proportional hazard mixed model were used to estimate
phlebotomine mortality due to different treatments.
Results: Fluralaner was the only compound that showed significant phlebotomine mortality. Fluralaner maintained
the phlebotomine mortality between 60–80% for 30 days after treatment. In trial 1 we found that fluralaner increased
the risk of death by 1.9 times (95% CI: 1.02–3.6) and 1.7 times (95% CI: 1.09–2.6) at days 2 and 4 after treatment. The
Cox model resulted in an increase of 1.47 (95% CI: 1.1–1.96) times in hazard risk at day 2 and 1.89 (95% CI: 1.35–2.45) at
day 4 after treatment.
In trial 2 we found that fluralaner increased the risk of death by 1.64 times (95% CI: 1.16–2.54) and 1.97 times (95% CI: 1.
23–3.17) at days 14 and 32. The hazard risk was also increased by 1.92 (95% CI: 1.4–2.64) times at day 14 after treatment.
Phlebotomine survival including all experimental days was significantly lower in the fluralaner group in both trials.
Conclusions: A single oral treatment of fluralaner in dogs induces phlebotomine mortality. Systemic insecticides in dogs
should be considered as a potential preventive measure of ZVL.
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Background
Zoonotic visceral leishmaniasis (ZVL) is a public health
concern in some regions (e.g. Brazil, Mediterranean basin,
Iran and China) where it causes a significant number of
human cases, particularly in children [1]. The disease can
be lethal if appropriate treatment is not provided [2]. The
causal agent is a protozoan parasite named Leishmania
(Leishmania) infantum. Different mammal species are res-
ervoirs but dogs are considered to be the main one [3]
and phlebotomine sand flies are the proven vector [4].
Current control measures (e.g. culling of infected dogs,
insecticide spraying, dog collars) have a limited impact on
ZVL transmission for several reasons [5]. New cost-
effective vector control methods are required. Systemic
insecticides that are easily administered to dogs (e.g. or-
ally) and kill sand flies biting on them for a significant
amount of time, could be used as an alternative or com-
plement to control ZVL in endemic regions [6].
A number of systemic insecticides for dogs are cur-
rently available. These are mainly registered to treat and
prevent ectoparasitic infestations such as fleas, ticks, and
mites [7–9]. Others are used to prevent dirofilarial infec-
tions in dogs [10]. Systemic insecticides enter into the
circulatory system to be distributed through the entire
body. The route of administration can be oral, paren-
teral, or topical [11].
The compounds considered as systemic insecticides
currently used in dogs are isoxazolines (fluralaner, afox-
oloner, sarolaner), spinosyns (spinosad), neonicotinoids
(nitenpyram), and macrocyclic lactones (ivermectin, sela-
mectin, moxidectin, and doramectin). Isoxazolines are
antagonist of the gamma-aminobutyric acid (GABA)-
gated chloride channels. Several studies have demon-
strated the isoxazolines efficacy against fleas and ticks
infestations after a single oral administration [12–14].
The duration of the effect ranges from four (afoxoloner,
sarolaner) to 12 weeks (fluralaner). Macrocyclic lactones
act as GABA agonists and agonists of the glutamate-
gated chloride channels. Systemically distributed macro-
cylic lactones are used to control heartworm infections
in dogs (Dirofilaria immitis) [15].
Some of these insecticides have phlebotomine mortality
effect as shown in experimental [16, 17] and field studies
[18]. There is, however, no evidence of their effect on sand
flies when administered to dogs. In this study we evaluate
the phlebotomine mortality effect post-feeding in blood of
dogs treated with four systemic insecticides: moxidectin,
spinosad, fluralaner and afoxolaner.
Methods
Systemic insecticides
The insecticides evaluated in this study were selected
based on their: (i) phlebotomine mortality showed in
laboratory experiments or a potential phlebotomine
mortality based on the insecticide mechanism of action;
(ii) optimal plasma concentration for the phlebotomine
mortality effect based on in vivo or in vitro studies; (iii)
long-lasting action (> 12 weeks); (iv) ease of administra-
tion (e.g. oral); and (v) availability as commercial prod-
ucts for dogs [6]. The four compounds evaluated were:
Guardian®SR, Elanco (moxidectin); Comfortis®, Elanco
(spinosad); Bravecto®, Merck Animal Health (fluralaner);
and NexGard®, Merial (afoxolaner). All the products
where administered just once and following the label in-
dications: Guardian®SR, subcutaneous injection dose of
0.17 mg/kg body weight; Comfortis®, chewable table 425
mg for dogs > 6–9.4 kg; Bravecto®, chewable tablet 500
mg for dogs > 4.5–10 kg, and NexGard®, chewable tablet
28.3 mg for dogs > 4–10 kg. Fluralaner was administered
on fasted dogs in trial 1 and on fed dogs in trial 2 as it
has shown to increase bioavailability [19].
Study design
The study was run between February 2016 and June
2017. Two randomized controlled trials were con-
ducted in dogs. The first clinical trial (trial 1) was de-
signed to evaluate the effect of four systemic
insecticides (see above). The compound showing the
best performance in trial 1 was further evaluated in
the second clinical trial (trial 2). Trial 2 was designed
to measure the phlebotomine mortality of the selected
compounds for three months. The phlebotomine mor-
tality of the systemic insecticides was measured by
comparing the mortality of sand flies feeding on
blood from treated and control dogs.
Study site and dogs
The study was conducted in one breeding kennel located
in the Province of Huesca (Spain). Dogs from 1–5 years-
old, from the breeds Parson Rusell (trial 1: n = 7; trial 2:
n = 11), Jack Rusell (trial 1: n = 13; trial 2: n = 9) and
Teckel (trail 1: n = 10) participated in the study. To
avoid contamination, no insecticide treatment was pro-
vided to the dogs or the kennel in the three months pre-
ceding the study. All of the dogs each had a microchip
and were examined by a veterinarian at the start of the
study. Only healthy dogs were enrolled. The enrolled
dogs were kept in the kennel with their regular routines
and diet for the whole study period.
Sample size
The sample size calculation in trial 1 aimed at detecting
at least a 65% increase in phlebotomine mortality at 24
h after feeding on a treated dog’s blood collected up to
30 days post-treatment. Trial 2 was powered to detect at
least 45% increase in phlebotomine mortality 24 h after
feeding on a treated dog’s blood up to 90 days post-
treatment. These calculations were done assuming 20%
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phlebotomine mortality in control group, alpha error of
0.05 and 80% power [20]. The sample size calculation re-
sulted in 6 dogs per treatment group in trial 1 (24 dogs
in 4 treatment groups of equal size and 6 dogs in con-
trol) and 10 dogs per treatment group in trial 2 (10 dogs
in treatment and 10 dogs in control).
Randomization and allocation
We selected dogs (trial 1: n = 30; trial 2: n = 20) of
similar size from the kennel that participated in the
study. Once the dogs were selected the randomization
was done using the dogs’ microchip numbers. To
achieve balance across treatment groups a stratified
permuted block randomization was used [21]. Dogs
were subdivide into strata (breed and gender) then a
permuted block randomization was used for each
stratum [22]. The permuted block randomization was
performed using the sample function in R (version 3.
3) [23]. The only person aware of the randomization
results was the researcher who administered the treat-
ments. Researchers responsible for taking the blood
samples and performing the membrane feedings were
blind to the treatment allocation.
Treatments in the intervention groups were adminis-
tered in a unique dose at Day 0 following the label indi-
cations. Comfortis®, Bravecto®, and NexGard® were given
orally and Guardian® SR was administered subcutane-
ously. The control dogs received no treatment.
Blood samples from the cephalic or jugular veins were
taken on days 2, 4, 21 and 31 post-treatment in trial 1
and on days 0, 2, 4, 7, 14, 18, 32, 39, 51 and 84 in trial 2
(Additional file 1: Figure S1). At each time-point 4 ml of
blood per dog was kept in heparinized tubes preserved
at -21 °C for 3–9 months until the bioassays were per-
formed. Blood samples were identified with the date of
collection and the dog’s microchip number.
Outcomes
The effect of the four systemic insecticides was mea-
sured by membrane feeding bioassays using reared Phle-
botomus papatasi sand flies from the School of
Veterinary Medicine at the University of Zaragoza. To
summarize, the colony was maintained at 30 °C, 90%
relative humidity, and a photo period of 17:7 h (light:
dark photocycle). The sand flies were deprived of
sucrose solution 12 h before the bioassays. The dog’s
blood was thawed at room temperature (23 °C) on the
day of the bioassay. Two- to seven-days-old P. papatasi
sand flies were exposed to the blood collected from the
dogs in the study using Hemotek (Discovery Workshops,
Lancashire, UK [24]). Hemotek kept the blood at 37 °C
and chicken skin membrane was used to mimic blood-
feeding on-animal conditions.
The membrane feeding bioassays for each blood sam-
ple were performed with around 40 females of P. papa-
tasi mixed with some males. The sand flies were allowed
to feed on the dog’s blood for at least 1.5 h or until 15
females were observed to be fully engorged; a total of
1800 fully engorged sand flies were needed for trial 1
and 3000 for trial 2.
After the membrane feeding, the 15 fully engorged
sand flies were placed into individual plastic cups of 90
ml and 60 mm diameter. An orifice of 45 mm was made
in the bottom of the cup and covered with clay to keep
humidity high inside the cup. The selection of the fully
engorged sand flies was made by visual observation. Su-
crose solution was provided to all sand flies. Phleboto-
mine mortality was recorded every 24 h for five days.
Statistical analysis
The average mortality and its 95% confidence interval (CI)
of the 15 fully engorged sand flies were calculated per
treatment group (control, afoxolaner, flularaner, moxidec-
tin and spinosad), sampling day (trial 1: 2, 4, 21 and 31;
and trial 2: days 0, 2, 4, 7, 14, 18, 32, 39, 51 and 84) and
mortality recording time (24, 48, 72, 96 and 120 h).
Two different statistical analyses were used to assess
the anti-phlebotomine mortality of systemic insecticides.
First, a mixed model for a negative binomial logistic re-
gression [25] was performed to estimate differences in
phlebotomine mortality 24 h after blood ingestion be-
tween treatment and control groups over time (30 days
in trial 1 and 60 days in trial 2). The model analyzed the
incidence rate (IR) as the response variable, that is, the
number of fully engorged sand flies dead in 24 h given
the total number of fully engorged sand flies (offset).
The exponential of the model estimates are the inci-
dence rate ratios (IRR) comparing each treatment to
control. The variable dog was included as a random
effect to account for the repeated sampling. Sampling
day, treatment, and their interaction were the explana-
tory variables. The interaction term was included to be
able to capture differences among the treatments in their
efficacy over time (e.g. one treatment could have the
highest effect 2 days after administration but another
treatment could have the highest effect 4 days after
administration). Secondly, survival analyses were con-
ducted. Kaplan Meier curves were used to represent the
phlebotomine mortality up to 5 days post-feeding for
treatment and control groups. Then, a Cox proportional
hazard mixed model for the number of dead sand flies
was used to estimate the mean increase in the risk of
phlebotomine mortality per day in treated groups com-
pared to control. The Cox proportional hazard model
response variable is the effect of treatment in the hazard
rate of a phlebotomine dying (i.e. probability of death in
24 h) after feeding on a dog’s blood. The exponential of
Gomez et al. Parasites & Vectors  (2018) 11:230 Page 3 of 9
the model estimates are the hazard rate ratios (HRR)
comparing each treatment to control. As for the negative
binomial model, dog was included as a random effect
and sampling day, treatment, and their interaction were
the explanatory variables. The z-statistic was used to de-
termine statistical significance of the estimates obtained
from both models. Bayesian information criterion (BIC)
was used to select the best models.
All the analyses were conducted in R (version 3.3)
[23]. The MASS package [26] was used to conduct de
negative binomial regression. The survival and coxme
packages [27, 28] were used to conduct the Kaplan
Meier curves and the Cox proportional hazard mixed
model respectively.
Results
Trial 1
Six dogs per group were included in trial 1. Gender and
breed were evenly distributed among groups (Additional
file 2: Table S1). No adverse effects related to the admin-
istration of the treatments were observed in any dog.
The total number of fully engorged sand flies evalu-
ated was 1700. The total number of sand flies used per
treatment groups was 360, 316, 365, 330 and 329 for
control, afoxolaner, fluralaner, moxidectin and spinosad,
respectively. Phlebotomine mortality, the corresponding
percentage and its 95% CI from the mortality observed
at 24, 48, 72, 96 and 120 h after blood-feeding for treat-
ment and control groups and sampling day are reported
in Additional file 2: Table S2.
Compared to control, phlebotomine mortality 24 h
post-feeding was higher in the sand flie group fed in
blood samples of dogs treated with fluralaner at days 2
(55%; 95% CI: 45–65%) and 4 (77%; 95% CI: 68–86%)
post-insecticide-treatment. The phlebotomine mortality
for the fluralaner group was similar to the control group
at days 21 (37%; 95% CI: 27–47%) and 31 (43%; 95% CI:
32–53%) post-treatment. No differences were observed
in the phlebotomine mortality in the other treatments.
The negative binomial mixed model confirmed the pre-
vious observations. Treating dogs with fluralaner
increased the risk of death for sand flies by 1.9 (95% CI:
1.02–3.6) and 1.7 (95% CI: 1.09–2.6) times at day 2 and
4, respectively, compared to untreated dogs. None of the
treatments had an effect on phlebotomine mortality at
days 21 and 31 (Table 1 and Fig. 1a).
Kaplan Meier (KM) curves also indicated that flurana-
ler was the only compound that had a phlebotomine
mortality effect. At days 2 and 4 the KM curves showed
the biggest difference in phlebotomine survival compar-
ing fluralaner with control at 24 and 48 h after blood-
feeding. At 80 h after blood-feeding, phlebotomine sur-
vival is between 0 and 20% with no differences among
days or treatment groups (Additional file 3: Figure S2).
These observations were confirmed by the cox propor-
tional hazard model that showed significant increase in
hazard risk (HR) only for the fluralaner group on days 2
and 4 after treatment (Additional file 4: Figure S3). The
hazard risk in fluralaner treated dogs was 1.47 (95% CI:
1.1–1.96) times higher than control at day 2 after treat-
ment. This hazard increased to 1.89 (95% CI: 1.35–2.45)
at day 4 after treatment (Table 2). However, at days 21
and 31 after treatment the effect of fluralaner de-
creases and the hazard ratio is no longer significantly
above 1 (Table 2 and Fig. 2a).
Trial 2
Ten dogs per group were included in trial 2. Gender and
breed were evenly distributed among groups (Additional
file 2: Table S1). No adverse effects related to fluranaler
administration were observed.
The total number of fully engorged sand flies evalu-
ated was 2982: 1347 for fluralaner and 1635 for the
Table 1 Trial 1 results from the negative binomial mixed model
that included treatment group, sample day and their interaction
as fixed effects and dog as random effect. Results are presented
as the incidence rate ratio (IRR) which is the increase in the rate
of incidence compared with control at each sampling day
Covariates effecta IRRb 95% CI P-value
Day 2: Control Reference – –
Afoxolaner 1.39 0.74–2.67 0.31
Fluralaner 1.94 1.14–3.39 0.01*
Moxidectin 0.60 0.26–1.29 0.21
Spinosad 0.90 0.43–1.80 0.77
Day 4: Control Reference – –
Afoxolaner 1.34 0.82–2.18 0.23
Fluralaner 1.68 1.05–2.71 0.03*
Moxidectin 0.77 0.45–1.31 0.34
Spinosad 1.02 0.61–1.70 0.92
Day 21: Control Reference – –
Afoxolaner 1.11 0.67–1.89 0.67
Fluralaner 0.81 0.47–1.38 0.45
Moxidectin 0.91 0.54–1.53 0.73
Spinosad 0.96 0.57–1.61 0.89
Day 31: Control Reference – –
Afoxolaner 1.51 0.81–2.89 0.20
Fluralaner 1.21 0.64–2.31 0.55
Moxidectin 1.33 0.65–2.74 0.41
Spinosad 1.41 0.77–2.66 0.27
aThe covariate effects used control group at each corresponding day after
treatment as baseline comparison [Pr(>|z|)]
bIncidence rate ratio, as the ratio between the incidence rate in control group
and the incidence rate for each treatment group, at the corresponding
sampling day after treatment
*Significance level defined at α = 0.05
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control group. Phlebotomine mortality, the correspond-
ing percentage and its 95% CI from the mortality ob-
served at 24, 48, 72, 96 and 120 h after blood-feeding for
treatment and control groups and sampling day are re-
ported in Additional file 2: Table S3.
Compared to the control, phlebotomine mortality 24 h
after blood-feeding was higher for the fluralaner group
at days 14 (85%; 95% CI: 78–90%) and 32 (60%; 95% CI:
52–68%) after treatment (Additional file 4: Figure S3).
The negative binomial mixed model confirmed that
treating dogs with fluralaner increased the risk of death
for sand flies by 1.64 (95% CI: 1.16–2.54) and 1.97 (95%
CI: 1.23–3.17) times at day 14 and 32 after treatment re-
spectively (Table 3 and Fig. 1b).
Kaplan Meier (KM) curves also indicated that fluralaner
had phlebotomine mortality. For each day of the trial the
KM curve showed the biggest difference in phlebotomine
survival at 24 h after blood-feeding. At 80 h after blood-
feeding phlebotomine survival is between 0 and 10% with
no differences between fluralaner and control (Additional
file 5: Figure S4). The cox proportional hazard model
showed significant increase in hazard risk (HR) only on
day 14 after treatment. The hazard risk in fluralaner
treated dogs was 1.92 (95% CI: 1.4–2.64) times higher than
control at 14 days after treatment (Table 4 and Fig. 2b).
The mixed models of both trials were run with dog as
random effect. However, this random effect was significant
by likelihood ratio test (chi-square test; trial 1, df = 29 P =
4. 5609e-10; trial 2, df = 19, P = 6.627005e-12) only for the
Cox proportional hazard models.
Discussion
A single dose of Bravecto® chewable tablet (25 mg/kg of
fluralaner) administered to dogs showed a phlebotomine
mortality effect. The phlebotomine mortality ranged
Fig. 1 Probability of death for a phlebotomine 24 h after blood-feeding for each treatment group and sampling day estimated from a mixed
model for a negative binomial logistic regression. The variable dog was included as a random effect, treatement, days after treatment, and their
interaction were covariates. a Trial 1: afoxolaner vs fluralaner vs moxidectin vs spinosad vs control. b Trial 2: fluralaner vs control
Table 2 Trial 1 results from the cox proportional hazard model
that included treatment group, sample day and their interaction
as fixed effects and dog as random effect. Results are presented
as the hazard rate ratio (HRR) which is the increase in the
hazard rate compared with control at each sampling day
Covariates effecta HRRb 95% CI P-value
Day 2: Control Reference – –
Afoxolaner 1.13 0.85–1.56 0.45
Fluralaner 1.47 1.10–1.96 < 0.001*
Moxidectin 0.73 0.51–1.01 0.06
Spinosad 0.76 0.54–1.08 0.08
Day 4: Control Reference – –
Afoxolaner 1.25 0.93–1.67 0.08
Fluralaner 1.83 1.36–2.45 < 0.001*
Moxidectin 0.84 0.62–1.13 0.17
Spinosad 0.74 0.53–1.02 0.33
Day 21: Control Reference – –
Afoxolaner 1.39 0.98–1.86 0.07
Fluralaner 0.96 0.72–1.28 0.91
Moxidectin 1.06 0.78–1.39 0.55
Spinosad 1.04 0.76–1.38 0.61
Day 31: Control Reference – –
Afoxolaner 1.42 0.99–1.93 0.08
Fluralaner 1.25 0.93–1.68 0.43
Moxidectin 1.12 0.65–1.64 0.57
Spinosad 0.99 0.73–1.32 0.37
aThe covariate effects used control group at each corresponding day after
treatment as baseline comparison [Pr(>|z|)]
bHazard rate ratio, as the ratio between the hazard rate in control group and
the hazard rate for each treatment group, at the corresponding sampling day
after treatment
*Significance level defined at α = 0.05
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Fig. 2 Hazard rate ratio compared with control for each treatment group and sampling day estimated from a mixed cox proportional hazard
model. The variable dog was included as a random effect treatment, days after treatment, and their interaction were covariates. a Trial 1:
afoxolaner vs fluralaner vs moxidectin vs spinosad vs control. b Trial 2: fluralaner vs control
Table 3 Trial 2 results from the negative binomial mixed model
that included treatment group, sample day and their interaction
as fixed effects and dog as random effect. Results are presented
as the incidence rate ratio (IRR) which is the increase in the rate
of incidence compared with control at each sampling day
Covariates effecta IRRb 95% CI P-value
Day 2: Control Reference – –
Fluralaner 1.24 0.78–1.96 0.35
Day 4: Control Reference – –
Fluralaner 1.40 0.90–2.18 0.13
Day 7: Control Reference – –
Fluralaner 1.42 0.92–2.19 0.11
Day 14: Control Reference – –
Fluralaner 1.64 1.16–2.54 0.025*
Day 18: Control Reference – –
Fluralaner 1.22 0.77–1.91 0.38
Day 32: Control Reference – –
Fluralaner 1.97 1.23–3.17 0.004*
Day 39: Control Reference – –
Fluralaner 0.92 0.59–1.44 0.73
Day 51: Control Reference – –
Fluralaner 1.24 0.93–1.66 0.14
Day 84: Control Reference – –
Fluralaner 0.93 0.68–1.27 0.68
aThe covariate effects used control group at each corresponding day after
treatment as baseline comparison [Pr(>|z|)]
bIncidence rate ratio, as the ratio between the incidence rate in control group
and the incidence rate for each treatment group, at the corresponding
sampling day after treatment
*Significance level defined at α = 0.05
Table 4 Trial 2 results from the Cox proportional hazard model
that included treatment group, sample day and their interaction
as fixed effects and dog as random effect. Results are presented
as the hazard rate ratio (HRR) which is the increase in the
hazard rate compared with control at each sampling day
Covariates effecta HRRb 95% CI P-value
Day 2: Control Reference – –
Fluralaner 0.97 0.70–1.36 0.90
Day 4: Control Reference – –
Fluralaner 1.12 0.70–1.53 0.43
Day 7: Control Reference – –
Fluralaner 1.27 0.94–1.72 0.12
Day 14: Control Reference – –
Fluralaner 1.92 1.40–2.64 <0.0001*
Day 18: Control Reference – –
Fluralaner 1.15 0.84–1.59 0.36
Day 32: Control Reference – –
Fluralaner 1.28 0.94–1.75 0.10
Day 39: Control Reference – –
Fluralaner 0.86 0.65–1.15 0.33
Day 51: Control Reference – –
Fluralaner 0.86 0.64–1.15 0.22
Day 84: Control Reference – –
Fluralaner 0.73 0.53–1.05 0.09
aThe covariate effects used control group at each corresponding day after
treatment as baseline comparison [Pr(>|z|)]
bHazard rate ratio, as the ratio between the hazard rate in control group and
the hazard rate for each treatment group, at the corresponding sampling day
after treatment
*Significance level defined at α = 0.05
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from 60 to 80% up to 30 days after treatment. This mor-
tality was lower than the mortality reported in fleas. In
fleas, the main the target of the product, the mortality
reported was 100% 24 hours after infestation during 12
weeks after treatment [12, 29, 30]. The lower mortality
effect found in phlebotomine sand flies comparing with
the mortality found in flea studies, besides the differ-
ences in the study design [direct feeding (fleas) versus
membrane feeding], could be due to their differences in
feeding behavior. For example, sand flies ingest 1 μl of
blood or less [31] while fleas ingest 110 μl [32] of blood,
sand flies take an average of six minutes to feed on
blood [33] while fleas take an average of 25 minutes
[34]. These feeding characteristics could influence the
amount and the bioavailability of the insecticide.
The other compounds tested: spinosad, afoxolaner,
and moxidectin did not show significant increase in
phlebotomine mortality. This may be due in part to the
low concentration used in this study. For example, we
administered spinosad at 45–70 mg/kg; however, previ-
ous studies in rodents showed that spinosad treated diet
had phlebotomine mortality when administered at 5000
mg/kg but no significant mortality was observed at 500
mg/kg of spinosad [35]. Nevertheless, spinosad, as well
as afoxolaner and fluralaner administered at label con-
centration showed to have significant lethal effects on
triatomines directly feeding on dogs [36]. Fluralaner and
afoxolaner killed 100% of the triatomines for 51 days
after oral administration. Lower mortality (50–70%) was
observed in the spinosad group.
Furalaner showed a significant increase in sand fly
mortality in both trials 1 and 2. However, the two trials
differ in the onset of action and the duration of it. These
differences can be explained by (i) higher phlebotomine
mortality in control group in trial 2 (phlebotomine mor-
tality at day 2: 63%, CI 53,72) than in trial 1 (day 2: 28%,
CI 19, 38), and (ii) the influence of food on the pharma-
cokinetics (PK) of fluralaner. More precisely, for the first
trial, the chewable tablet of fluralaner was administered
early in the morning before feeding the dogs: the dogs’
last meal was about 20 hours before administration. In
trial 2, the chewable tablet was administered after the
dogs received half of their daily food ration. One PK
study showed that when fluralaner is administered with
food, its bioavailability is duplicated [20].
The mortality associated to the different treatments ob-
served in this study may be an underestimation. Mortality
in the control group 24 hours after blood-feeding was
much higher (50%, Additional file 4: Figure S3) than ex-
pected (20%) and variable (e.g. phlebotomine mortality in
trial 2 range from 34% in day 32 to 63% in day 2). The
high mortality reduced the power of the trials and the
variability may explain the inconsistencies on the effect
observed on consecutive sampling days (e.g, statically
significant mortality on day 14 and 32 but not on day 21
in trial 2). Despite the high mortality in the control group
we demonstrated that systemic insecticides, such as flura-
laner have mortality effect against phlebotomine sand flies.
Variations of mortality in controls may be due to (i) use
membrane feeding instead of direct feeding; (ii) low num-
ber of sand flies per membrane feeding; or (iii) phleboto-
mine environmental temperature or humidity. Reducing
mortality in control group may allow better estimation of
mortality due to systemic insecticides.
Conclusions
Despite the limitations, this study shows that a single
oral treatment of fluralaner in dogs induces phleboto-
mine mortality. This would indicate that administering
systemic insecticides to dogs could potentially be used
to control ZVL, but further work needs to be conducted
to define the requirements of compounds to be used in
a public health intervention, e.g. insecticide efficacy, dur-
ation of the efficacy, route of administration or the per-
centage of dogs treated in the community. Finally, a
clinical trial should be conducted to evaluate the impact
of administering systemic insecticides to dogs to control
ZVL in humans in endemic areas.
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Additional file 2: Table S1. Randomization results. Table S2. Trial 1,
sand fly mortality, percentage, and 95% CI at 24, 48, 72, 96 and 120 hours
after blood feeding for treatment group and sampling day. Table S3.
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and their interaction as explanatory variables and dog as random effect.
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Additional file 3 Figure S2. Trial 1, sand fly survival after feeding with
blood collected from dogs 2, 4, 21 and 31 days after treatment
administration. Groups: control (black); afoxolaner (green); fluralaner (red);
moxidectin (yellow); and spinosad (blue). (TIFF 66 kb)
Additional file 4 Figure S3. Sand fly mortality percentage and its 95%
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Additional file 5 Figure S4. Trial 2, sand fly survival after feeding with
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treatment administration by treatment groups: control (black), fluralaner
(red). (TIFF 37 kb)
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